Related Experiment Video
Updated: Jan 30, 2026
08:15
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
963
Diabetic nephropathy: An update on pathogenesis and drug development.
Vikram Rao A/L B Vasanth Rao1, Sean Hong Tan2, Mayuren Candasamy3
1School of Postgraduate Studies, International Medical University, No 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia.
Diabetes & Metabolic Syndrome
|January 16, 2019
Summary
Diabetic nephropathy (DN) is a leading cause of kidney failure. Understanding its molecular pathways is crucial for developing effective treatments and improving patient outcomes.
Area of Science:
- Nephrology
- Endocrinology
- Molecular Biology
Background:
- Diabetic nephropathy (DN) is a significant complication of diabetes and a primary cause of end-stage renal disease.
- Current treatments for DN are limited, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To review the molecular pathways involved in the pathogenesis of DN.
- To identify potential drug targets and assess the status of clinical trials for DN treatments.
Main Methods:
- A comprehensive literature search was conducted on the pathogenesis, pathophysiology, drug targets, and clinical trials related to DN.
- Information on diagnostic biomarkers and consequences of DN was also gathered.
Main Results:
- DN is characterized by microalbuminuria, macroalbuminuria, and specific morphological changes in the kidneys.
- Key pathways implicated in DN progression include the renin-angiotensin-aldosterone system, inflammation, and genetic factors.
- Several drug candidates targeting pathways like epidermal growth factor and TGFβ1 are in clinical trials, but some have failed due to efficacy or safety issues.
Conclusions:
- A deeper understanding of DN pathogenesis is essential for advancing drug development.
- Further research is needed to identify more effective and safer therapeutic strategies for diabetic nephropathy.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
642
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
642
01:20Asthma: Pathogenesis and Management
1.3K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.3K
01:23Cystic Fibrosis: Pathogenesis
871
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
871
01:20Pathophysiology of Diabetes
3.6K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.6K
01:20COPD: Pathogenesis and Clinical Features
1.8K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.8K
01:10In Vitro Drug Release Testing: Overview, Development and Validation
341
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
341